Filing Details
- Accession Number:
- 0001638599-17-000926
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-08 17:06:12
- Reporting Period:
- 2017-09-08
- Accepted Time:
- 2017-09-08 17:06:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
879169 | Incyte Corp | INCY | Services-Commercial Physical & Biological Research (8731) | 943136539 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1087939 | Julian Baker | 667 Madison Avenue, 21St Floor New York NY 10065 | Yes | No | Yes | No | |
1087940 | Felix Baker | 667 Madison Avenue, 21St Floor New York NY 10065 | Yes | No | Yes | No | |
1263508 | Baker Bros. Advisors Lp | 667 Madison Avenue, 21St Floor New York NY 10065 | Yes | No | Yes | No | |
1363364 | Baker Brothers Life Sciences Lp | 667 Madision Avenue, 21St Floor New York NY 10065 | Yes | No | Yes | No | |
1551138 | 14159, L.p. | 667 Madision Avenue, 21St Floor New York NY 10065 | Yes | No | Yes | No | |
1551139 | 667, L.p. | 667 Madision Avenue, 21St Floor New York NY 10065 | Yes | No | Yes | No | |
1580575 | Baker Bros. Advisors (Gp) Llc | 667 Madision Avenue, 21St Floor New York NY New York | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-09-08 | 12,569 | $132.00 | 4,386,818 | No | 4 | P | Indirect | See Footnotes |
Common Stock | Acquisiton | 2017-09-08 | 85,402 | $132.00 | 29,247,347 | No | 4 | P | Indirect | See Footnotes |
Common Stock | Acquisiton | 2017-09-08 | 2,029 | $132.00 | 789,416 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 58,632 | Direct | |
Common Stock | 61,049 | Direct | |
Common Stock | 33,410 | Indirect | See Footnotes |
Footnotes
- Reflects shares of common stock of Incyte Corporation (the "Issuer") held directly by Julian C. Baker.
- Reflects shares of common stock of the Issuer held directly by Felix J. Baker.
- Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in 33,410 shares of Common Stock of the Issuer directly held by FBB Associates. Julian C. Baker and Felix J. Baker are the sole partners of FBB Associates. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Julian C. Baker or Felix J. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- On September 8, 2017, 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159 ("14159", and together with 667 and Life Sciences the "Funds") purchased 12,569, 85,402 and 2,029 shares of the Common Stock, respectively of the Issuer, pursuant to an underwritten public offering.
- After giving effect to the transactions reported herein and as a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,386,818 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
- After giving effect to the transactions reported herein and as a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 29,247,347 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
- After giving effect to the transactions reported herein and as a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 789,416 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
- Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
- Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.